Compare Smith & Nephew plc (SNN) vs Visa Inc (V) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Smith & Nephew plc vs Visa Inc — how do they compare? Smith & Nephew plc trades at $27.72 (market cap $11.63B), while Visa Inc trades at $368.99 (market cap $693.57B). The key difference: Visa Inc is far larger — about 59.6× Smith & Nephew plc's market cap, and Smith & Nephew plc pays the higher dividend (2.85%). Which is the better fit depends on your goals.
| SNN | V | |
|---|---|---|
Market Cap | $11.63B | $693.57B |
Sector | Health | Financials |
52-Week High | $38.53 | $384.14 |
52-Week Low | $27.80 | $295.52 |
Enterprise Value | $14.66B | $704.15B |
Dividend Yield | 2.85% | 0.73% |
Volume | — | 10,431,336 |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Smith & Nephew (SNN) trades at $27.87, down 3.46% over 24 hours and near its 52-week low. The stock shows a bearish technical trend with mixed sentiment; recent earnings have mostly beaten expectations, but Q2 2026 revenue growth missed and guidance was cut. Fundamentals are solid with revenue rising to $6.16B in 2025 and net income margin improving to 10.08%, though debt levels have increased. The company faces competitive pressures in key markets like U.S. Orthopaedics.
Outlook is cautious: valuation ratios like P/E of 18.96 are reasonable, but analyst consensus is Hold (65%) due to execution risks and CFO departure. Opportunities include innovation in surgical robotics and new product launches, but investors should monitor U.S. market weakness and debt management for sustained recovery.
Visa (V) trades at $368.64, down 1.71% on the day, amid a bullish technical setup with strong support at $366 and resistance at $372. The company reported robust fundamentals with Q2 2026 earnings beating estimates, revenue growth to $40B in 2025, and a net income margin of 50.78%. Recent news highlights Visa's push into AI-driven commerce and stablecoin partnerships, signaling innovation in payments.
Outlook remains positive with an analyst consensus price target of $430.93 (17% upside), supported by high profitability and strategic initiatives. Risks include fintech competition and regulatory pressures, but institutional ownership trends and a debt-to-asset ratio of 25.26% reflect financial stability. The stock presents a long-term growth opportunity with manageable headwinds.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Smith & Nephew plc
Smith & Nephew designs, manufactures, and markets orthopedic devices, sports medicine and arthroscopic technologies, and wound-care solutions. Roughly 42% of the U.K.-based firm's revenue comes from orthopedic products, and another 30% is sports medicine and ENT. The remaining 28% of revenue is from the advanced wound therapy segment. Roughly half of Smith & Nephew's total revenue comes from the United States, just over 30% is from other developed markets, and emerging markets account for the remainder.
Read more on SNN →About Visa Inc
Visa Inc. operates a retail electronic payments network and manages global financial services. The Company also offers global commerce through the transfer of value and information among financial institutions, merchants, consumers, businesses, and government entities.
Read more on V →
